
Lantern Pharma Inc.
$3.96
+0.1340 (3.50%)
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 32 | Nov 13, 2025 |
| 10-q | Quarterly Reports | 63 | Nov 12, 2025 |
| 4 | Insider transactions | 1 | Sep 23, 2025 |
| 4 | Insider transactions | 1 | Sep 23, 2025 |
| 4 | Insider transactions | 1 | Sep 23, 2025 |
| 4 | Insider transactions | 1 | Sep 23, 2025 |
| 4 | Insider transactions | 1 | Sep 23, 2025 |
| 8-k | 8K-related | 12 | Sep 23, 2025 |
| 4 | Insider transactions | 1 | Sep 23, 2025 |
| 4 | Insider transactions | 1 | Aug 20, 2025 |
Sign Up For LTRN Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Lantern Pharma (LTRN) is a client of RedChip Companies, Inc. LTRN agreed to pay RedChip Companies, Inc. 50,000 shares of Rule 144 stock for six months of investor awareness services, beginning in March 2026. RedChip intends to and will, if possible, sell all of its shares immediately upon removal of the restriction, and you may be buying as RedChip is selling. Previously, LTRN agreed to pay RedChip an $8,500 monthly cash fee, beginning in June 2025, for three months of investor awareness services, and a $10,000 monthly cash fee, beginning in April 2023, and 2500 shares of Rule 144 stock, for six months of RedChip investor awareness services. The shares were registered and RedChip sold its shares immediately. LTRN also agreed to pay RedChip a one-time $54,000 fee for a 10-day national TV ad campaign aired in June 2025. LTRN also agreed to pay RedChip a $104,000 fee for a six week national TV ad campaign aired weekdays from February 26 through April 15, 2024. RedChip’s president purchased 50,000 shares of LTRN stock at $1.27 per share in March 2026; these shares may be sold at any time, and you may be buying as they are sold.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.